Compare · MNKD vs NVS
MNKD vs NVS
Side-by-side comparison of MannKind Corporation (MNKD) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MNKD and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $286.95B, about 279.8x MNKD ($1.03B).
- Over the past year, MNKD is down 44.2% and NVS is up 14.6% - NVS leads by 58.8 points.
- MNKD has hit the wire 3 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 14 for MNKD).
- Company
- MannKind Corporation
- Novartis AG
- Price
- $3.05-4.54%
- $150.59+0.17%
- Market cap
- $1.03B
- $286.95B
- 1M return
- -14.92%
- +6.85%
- 1Y return
- -44.24%
- +14.59%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 3
- 0
- Recent ratings
- 14
- 25
MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-Ã inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest MNKD
- MannKind to Participate in the Chardan Healthcare Conference
- MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
- Director Binder Steven B. sold $128,478 worth of shares (39,051 units at $3.29), decreasing direct ownership by 5% to 713,258 units (SEC Form 4)
- Director Binder Steven B. sold $127,856 worth of shares (33,558 units at $3.81), decreasing direct ownership by 4% to 752,309 units (SEC Form 4)
- MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
- MannKind to Present at Upcoming Investor Conferences
- SEC Form 8-K filed by MannKind Corporation
- SEC Form 424B7 filed by MannKind Corporation
- Director Binder Steven B. sold $158,547 worth of shares (39,051 units at $4.06), decreasing direct ownership by 5% to 785,867 units (SEC Form 4)
- SEC Form 10-Q filed by MannKind Corporation
Latest NVS
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- The Quest to Repair What Multiple Sclerosis Takes Away